ArticleThe Lancet regional health. Western Pacific2026
Social network distribution of HIV self-tests among MSM in Australia: a prospective, non-randomised trial.
Article in The Lancet regional health. Western Pacific, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Leveraging social networks to expand HIV self-testing among culturally diverse MSM in Australia: insights from a CFIR-informed process evaluation.Frontiers in public health · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: HIV testing uptake among men who have sex with men (MSM) in Australia remains suboptimal, with lapses and extended testing intervals persisting despite established guidelines. Novel HIV testing strategies address these gaps, particularly among MSM underserved by clinic-based services. We evaluated uptake of HIV self-testing (HIVST) distributed using social network-based strategies among MSM in Australia. Methods: In this prospective, non-randomised trial (ACTRN12625000342415), HIV-undiagnosed MSM aged ≥18 years were recruited online on a rolling basis between Jan 30 and April 28, 2025. Participants comprised both test promoters (initially recruited individuals who received HIVST kits for personal use and distribution) and recipients (individuals who received a kit from a promoter). Test promoters each received four HIVST kits-one for personal use and three for distribution. Participants were invited to complete an online survey within three months of kit receipt. Recipients who completed the survey could enrol as second-wave test promoters and receive additional kits. Primary outcome: HIVST use within 7 days of receipt; secondary outcomes: use within 24 h, feasibility and acceptability. Associations with use were estimated using Poisson regression. Findings: Ninety-one test promoters received 364 HIVST kits (91 for personal use, 273 for distribution). All promoters used their own kit and completed the follow-up survey (100%). Among the first-wave recipients, 245 kits were survey-verified as used. Eight recipients subsequently enrolled as second-wave test promoters, distributing additional kits and yielding 15 survey-verified secondary recipients. In total, 351 participants completed follow-up surveys. Of respondents, 280 (80%) used the HIVST within 7 days, including 181 (52%) within 24 h. Use within 7 days was more common among participants without government-subsidised healthcare (adjusted rate ratio 1.16, 1.05-1.28; p = 0.004), those not tested in the past 3 months (3-6 months, 1.22 [1.02-1.45], p = 0.026; 7-12 months, 1.36 [1.16-1.60], p < 0.001; >12 months, 1.30 [1.11-1.53], p = 0.001; never tested, 1.31 [1.11-1.55], p = 0.002), and those spending little (1.36 [1.10-1.68]; p = 0.004) or no time (1.33 [1.06-1.66]; p = 0.015) with LGBTQ+ peers. Most participants found HIVST easy to use (99%) and would reuse it (88%). Interpretation: Social network-based distribution of HIVST is feasible and acceptable, with high HIVST kit usability and rapid uptake among MSM, supporting equitable HIV testing access. Funding: Australian National Health and Medical Research Council (NHMRC) Emerging Leadership Investigator Grant and an Australian Government Research Training Program scholarship.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.